Drug General Information
Drug ID
D0Q0OD
Former ID
DNCL001580
Drug Name
Secukinumab
Drug Type
Monoclonal antibody
Indication Severe plaque psoriasis [ICD10:L40] Approved [556264]
Psoriatic arthritis; Rheumatoid arthritis [ICD9: 696, 710-719, 714; ICD10:L40.5, M07, M05-M06] Phase 4 [525316], [542955], [551965]
Rheumatoid arthritis; Dry eye; Multiple sclerosis; Psoriatic arthritis; Type 1 diabetes mellitus; Alopecia areata; Atopic dermatitis [ICD10:E10, G35, H19.3, L20, L40, L40.5, M07, M05-M06] Phase 2 [889360], [889365], [889369], [889386], [889389], [889416], [889418], [889424], [889431], [889437]
Company
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
SuperDrug ATC ID
L04AC10
References
Ref 525316ClinicalTrials.gov (NCT02547714) Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A.
Ref 542955(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8078).
Ref 551965Clinical pipeline report, company report or official report of Novartis.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 889360ClinicalTrials.gov (NCT01250171) The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients
Ref 889365ClinicalTrials.gov (NCT01359943) Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate
Ref 889369ClinicalTrials.gov (NCT01426789) A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Ref 889386ClinicalTrials.gov (NCT01874340) Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Ref 889389ClinicalTrials.gov (NCT02044848) Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
Ref 889416ClinicalTrials.gov (NCT02594098) Secukinumab for Treatment of Atopic Dermatitis
Ref 889418ClinicalTrials.gov (NCT02599129) A Study of Secukinumab for the Treatment of Alopecia Areata
Ref 889424ClinicalTrials.gov (NCT02854163) Effect of Secukinumab in the Treatment of Psoriatic Arthritis
Ref 889431ClinicalTrials.gov (NCT03041038) The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
Ref 889437ClinicalTrials.gov (NCT03131570) Safety and Efficacy of Secukinumab in Mild Psoriasis

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.